The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
600
Change from baseline in UPDRS (Unified Parkinson's Disease Rating Scale) II + III total scores at end of maintenance, for sumanirole compared to placebo
To assess the safety profile of sumanirole; the benefit of sumanirole in quality of life measures, and change from baseline in UPDRS II + III total scores at end of maintenance, for sumanirole compared to ropinirole
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Hot Springs, Arkansas, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Irvine, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Loma Linda, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Oceanside, California, United States
Pfizer Investigational Site
San Francisco, California, United States
...and 92 more locations